Accessibility Menu
BeOne Medicines Ag logo

BeOne Medicines Ag(SEHK) 6160

Market CapHK$316.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+110%
5 Year+14%
1 Year+17%
1 Month+11%
HK$212.80
-1.21%
-2.60Today
BeOne Medicines Ag last closing stock price
MetricPriceDate
Last closeHKD 215.402026-08-31
BeOne Medicines Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.71%HKD 221.402026-08-24
1 month+11.03%HKD 194.002026-07-31
3 month+27.61%HKD 168.802026-06-02
Year to date+20.13%HKD 179.302025-12-31
1 year+16.94%HKD 184.202025-08-29
3 year+69.34%HKD 127.202023-08-31
5 year+13.91%HKD 189.102021-09-01
Since inception+109.72%HKD 107.002018-08-08

BeOne Medicines Ag Financials at a Glance

Market Cap

HK$316.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.12B

Net Income (TTM)

$654.97M

EPS (TTM)

HK$3.41

P/E Ratio

63.08

Dividend

HK$0.00

Beta (Volatility)

-0.02 (Low)

Price

HK$212.80

Volume

1,454,223

Open

HK$215.40

Previous Close

HK$215.40

Daily Range

HK$212.00 - HK$216.40

52-Week Range

HK$153.00 - HK$235.60

Estimated Earnings Date

Nov 5, 2026

6160 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BeOne Medicines Ag

BeOne Medicines AG is a global biotechnology enterprise focused on developing innovative and affordable pharmaceutical products. The company aims to enhance therapeutic outcomes and improve patient access to essential medicines worldwide.

Products and Services
  • Development of groundbreaking pharmaceutical products
  • Focus on enhancing therapeutic outcomes
  • Commitment to broadening patient access to medicines
Growth Outlook
  • Recent quarterly revenue reached USD 1.51 billion, indicating strong demand
  • Trailing twelve months (TTM) gross profit margin stands at 87.16%
  • Operating income ratio improved to 16.51% in the latest quarter
Financial Highlights
  • Net income for Q1 2026 was USD 226.68 million, reflecting robust profitability
  • Cash and cash equivalents totaled USD 4.83 billion as of March 31, 2026
  • Current ratio of 3.64 indicates strong liquidity position
BeOne Medicines AG has established itself as a key player in the biotechnology sector, leveraging scientific research to create impactful healthcare solutions. The company's recent financial performance demonstrates a solid growth trajectory, with significant revenue generation and profitability. The high gross profit margin reflects effective cost management and a strong market position. Furthermore, the substantial cash reserves provide a strong foundation for future investments and operational flexibility. The current ratio indicates a healthy liquidity position, allowing the company to meet its short-term obligations effectively. Overall, BeOne Medicines AG presents a compelling opportunity for investors interested in the biotechnology industry.
AI Generated • Aug 2, 2026

Industry

Biotechnology

Sector

Health Care

Employees

12,000

CEO

John V. Oyler, MBA

Website

beonemedicines.com

Headquarters

Basel, BL 4051, CH

6160 Financials

Key Financial Metrics (TTM)

Gross Margin

87.82%

Operating Margin

15.06%

Net Income Margin

10.70%

Return on Equity

14.22%

Return on Capital

8.21%

Return on Assets

7.14%

Earnings Yield

1.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$316.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.47B

Volume

1.45M

Avg. Volume

5.26M

Financials (TTM)

Gross Profit

$5.38B

Operating Income

$922.19M

EBITDA

$1.10B

Operating Cash Flow

$1.49B

Capital Expenditure

-$175.33M

Free Cash Flow

$1.31B

Cash & ST Invst.

$5.10B

Total Debt

$1.14B

BeOne Medicines Ag Performance Analysis

BeOne Medicines Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 11,087,354,02421.3%
20232023-12-31USD 19,249,639,19673.6%
20242024-12-31USD 29,731,162,67454.5%
20252025-12-31USD 41,654,498,57540.1%
BeOne Medicines Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.4%
Q42025-12-316.0%
Q12026-03-310.8%
Q22026-06-3013.0%
BeOne Medicines Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -11.7024.6%
20232023-12-31USD -5.09-56.5%
20242024-12-31USD -3.68-27.7%
20252025-12-31USD 1.52N/A
BeOne Medicines Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3042.2%
Q42025-12-31-48.8%
Q12026-03-31243.2%
Q22026-06-306.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.71B

+29.6%

Gross Profit

$1.53B

+33.0%

Gross Margin

89.76%

N/A

Market Cap

HK$316.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$26.40M

N/A

Employees

12,000

N/A

Net Income

$237.01M

+151.3%

EBITDA

$392.71M

+218.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.10B

+85.0%

Total Debt

$1.14B

+11.5%

Accounts Receivable

$1.07B

+21.7%

Inventory

$732.60M

+45.7%

Long Term Debt

$930.36M

+365.1%

Short Term Debt

$212.85M

-74.2%

Return on Assets

7.14%

N/A

Return on Invested Capital

13.07%

N/A

Free Cash Flow

$414.83M

+107.6%

Operating Cash Flow

$462.82M

+75.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 6160

What is the current price of BeOne Medicines Ag?

BeOne Medicines Ag is trading at HK$212.80 per share.

What is the 52-week range for BeOne Medicines Ag?

Over the past 52 weeks, BeOne Medicines Ag has traded between HK$153.00 and HK$235.60.

How much debt does BeOne Medicines Ag have?

As of the most recent reporting period, BeOne Medicines Ag reported total debt of $16.07B.

How much cash does BeOne Medicines Ag have on hand?

BeOne Medicines Ag reported $41.24B in cash and cash equivalents in its most recent financial results.

What is BeOne Medicines Ag’s dividend yield?

BeOne Medicines Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services